Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash & Equivalents (2016 - 2026)

Ocular Therapeutix has reported Cash & Equivalents over the past 14 years, most recently at $666.7 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 90.66% year-over-year to $666.7 million; the TTM value through Mar 2026 reached $666.7 million, up 90.66%, while the annual FY2025 figure was $737.1 million, 87.98% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $666.7 million at Ocular Therapeutix, down from $737.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $737.1 million in Q4 2025 and troughed at $66.6 million in Q2 2023.
  • A 5-year average of $306.3 million and a median of $344.8 million in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 50.49% in 2023 and later soared 590.16% in 2024.
  • Year by year, Cash & Equivalents stood at $102.3 million in 2022, then surged by 91.4% to $195.8 million in 2023, then soared by 100.25% to $392.1 million in 2024, then skyrocketed by 87.98% to $737.1 million in 2025, then dropped by 9.55% to $666.7 million in 2026.
  • Business Quant data shows Cash & Equivalents for OCUL at $666.7 million in Q1 2026, $737.1 million in Q4 2025, and $344.8 million in Q3 2025.